SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction within the crypto community, with discussions focusing on its cultural significance and potential. Community members are actively sharing links to the Weedcoin website and DEX Screener, while emphasizing the importance of embracing and preserving the "culture." The coin is presented as more than just a cryptocurrency, but rather a movement.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its positive narrative and long-term vision, emphasizing conviction and community support. Bullish sentiment is fueled by the token's strong community and a belief that it's poised for significant growth, particularly within the Solana ecosystem. Discussions also highlight anticipation for potential listings and the project's alignment with broader crypto trends.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG is trending as the community celebrates its joke-inspired meme-coin status and continued presence on the Solana network. Active discussions revolve around the classic "What's Updog?" joke, with the community emphasizing its commitment and longevity in the crypto space, particularly its listing on Jupiter.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community anticipates the sunsetting of $PRQ, expecting it to remove arbitrage pressures and allow $REACT to trade more freely.  Enthusiasm is building around potential tier-1 exchange listings and the project's cross-chain smart contract technology, with some community members drawing comparisons to early-stage, high-potential cryptos. Bullish sentiment is fueled by recent integrations and partnerships, as well as a growing number of watchers.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Grayscale Ethereum Mini Trust ($ETH) is trending amidst fluctuating market conditions, as the community discusses its potential and key support levels. Community members are closely watching for a breakout past all-time highs, fueled by institutional interest and potential rate cuts, while also debating its relationship with other cryptocurrencies and treasury plays. Recent news of large Ethereum purchases, BlackRock's activity, and regulatory developments are adding to the buzz.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as community members discuss the company's potential for growth, driven by expansion plans including store openings and electric vehicle services. Some see it as a safe, long-term hold with the potential to test all-time highs. Bullish sentiment is fueled by analysis suggesting healthy financials and upcoming catalysts.

$GRIPPY is the sticky meme frog of Base — goofy, wholesome, and powered by pure meme energy.   Inspired by Furie-style chaos and community culture, Grippy isn’t just another frog, he’s a sticky symbol of resilience, humor, and diamond-handed holding. Built with zero taxes, a renounced contract, and liquidity locked, $GRIPPY launched as a true fair-play meme coin for the people.  The project thrives on organic growth, viral campaigns, and community-driven governance. With staking pools, a Grippy Dashboard, and merch/NFT drops in the roadmap, $GRIPPY is here to stick as Base’s No. 1 meme.

GRIPPY

Grippy is trending as community members discuss its potential, low market cap, and availability on Coinbase. Speculation around upcoming listings on Bitmart and Pionex, along with a potential partnership, is fueling excitement. Comparisons to other meme coins like Doge and Shiba Inu are also circulating.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

FLOKI is trending due to its recent listing on Robinhood, sparking excitement among investors despite some short-term price volatility. The community is discussing the potential for significant gains, drawing comparisons to past meme coin successes and highlighting Floki's ecosystem and utility. Some investors anticipate new all-time highs, while others focus on accumulating during dips, as the broader crypto market anticipates altcoin season.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending as a potential competitor to $AERO, with community members highlighting its recent launch on Base as a DUNA and locked tokenomics. Discussion centers on its potential for significant gains, driven by social media activity and comparisons to a larger market cap project, while some investors are drawn to its long-term potential.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as community members speculate on potential listings on major exchanges like Coinbase and Crypto.com, with some pointing to recent promotional activity as a positive sign. Many are discussing the possibility of the coin dropping multiple zeros in the near future, drawing comparisons to Shiba Inu's earlier growth and anticipating significant returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BTIG and H.C. Wainwright downgraded Vyne Therapeutics following topline results from the company’s Phase 2b trial of repibresib gel in nonsegmental vitiligo, which failed to meet both primary and secondary endpoints.BTIG analyst Julien Harrison downgraded the stock to ‘Neutral’ from ‘Buy’ and said the company will analyze the full dataset to guide next steps. He also noted that Vyne intends to seek a development and commercialization partner for repibresib.&nbsp;Harrison added that an update is expected in the coming weeks on both repibresib and VYN202, which is currently under partial clinical hold by the U.S. Food and Drug Administration.H.C. Wainwright analyst Joseph Pantginis also downgraded the stock to ‘Neutral’ from ‘Buy’ and removed the firm’s $4.5 price target, calling the trial outcome “a surprise” that “puts the company in a precarious position.”&nbsp;He said the firm will remain on the sidelines pending further clarity on repibresib, additional VYN202 data, or potential new asset acquisitions.Vyne said that the Phase 2b trial was a randomized, double-blind, vehicle-controlled study conducted at 45 sites across North America, enrolling 177 participants. The trial evaluated the once-daily topical administration of repibresib gel at 1%, 2%, and 3% concentrations compared to vehicle.&nbsp;The primary endpoint, defined as the proportion of patients achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index (F-VASI50) at week 24, was not met. The trial also missed a key secondary endpoint (F-VASI75).However, the company stated that the highest dose group showed a nominally statistically significant treatment effect in percent change from baseline (CFB) in both F-VASI and T-VASI scores at week 24.&nbsp;Vyne stated that the outcome was likely affected by a high vehicle effect and a higher-than-expected dropout rate in the active arms. As a result, the company has discontinued treatment in the extension phase and will terminate the trial.The company&nbsp;reported approximately $39.6 million in cash, cash equivalents, and investments as of June 30.&nbsp;Treatment-emergent adverse events (TEAEs) were more frequent in the repibresib arms, with application site pain being the most common. Eight subjects in the treatment group discontinued due to AEs, compared to none in the vehicle group. Most TEAEs were mild and resolved during the study.CEO David Domzalski said the company was disappointed by the outcome but remains confident in the potential of its InhiBET BET inhibitor platform.On Stocktwits, retail sentiment for Vyne was ‘extremely bullish’ late Wednesday amid&nbsp;an 11,800% surge in 24-hour message volume.One user said they went long on Vyne at&nbsp;$0.4189, calling the selloff part of the biotech cycle. “Every setback is a setup for a comeback,” they wrote, adding that while the vitiligo trial missed, the underlying science still showed promise.&nbsp;They also pointed to the FDA's recent move&nbsp;regarding the company’s psoriasis program and noted that Vyne has sufficient cash to operate into late 2026.<stembedurl>https://stocktwits.com/BulldogTheDip/message/623071473</stembedurl>Another user highlighted Vyne’s $39 million cash position, suggesting the stock could attract activist investors like Tang Capital Management. “If they step in, we could see a bounce,” the user wrote.<stembedurl>https://stocktwits.com/MadHatterTrades74/message/623051900</stembedurl><a href="https://stocktwits.com/symbol/VYNE">Vyne’s stock</a> has declined 88.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pharma stock. (Photo credit: Getty Images)

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

The company plans to seek a development and commercialization partner for repibresib and expects to provide an update on both repibresib and VYN202, which are currently under partial FDA clinical hold, in the coming weeks. 

Equity

Buy Rating for VYNE Therapeutics Amid Strong Financial Footing and Promising Clinical Trials

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on VYNE Therapeutics (VYNE Research Report). The associated price targe...

Buy Rating on VYNE Therapeutics: Promising Clinical Advancements and Market Potential

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on VYNE Therapeutics (VYNE Research Report), retaining the price target of $6.00...

Analyst Scoreboard: 4 Ratings For VYNE Therapeutics

Latest Ratings for VYNE
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.AssumesBuy May 2021HC Wainwright & Co.MaintainsBuy Oct 2020HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings for...

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company focused on developing proprietary...

VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Drop in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE  Get Free Report) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 35,800...

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

VYNE Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

VYNE
VYNE Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest VYNE News

VYNE VYNE Therapeutics Inc